CBD Brands names new director
8 March 2019 -

CBD Brands, a wellness brand involved in exploring the multiple therapeutic and medical uses of cannabidiol via a range of convenient products, has named Dr Glynn Wilson as its new director, it was reported yesterday.

Dr Wilson earlier served as the chairman & CEO of TapImmune Inc, prior to its merger with Marker Therapeutics Inc. He will draw from his more than 20 years of experience in the pharmaceutical industry to help expand clinical trials and research into the effectiveness of cannabidiol in the treatment of cancer and in combination therapy with existing cancer treatments on the market. Dr Wilson brings an extensive background in corporate and product management in the pharmaceutical and biotech industries to his role with CBD Brands. He formerly served as head of Drug Delivery at SmithKline Beecham Pharmaceuticals, research area head in Advanced Drug Delivery at Ciba-Geigy Pharmaceuticals, and most recently as chairman & CEO of TapImmune where he developed the clinical pipeline and up-listed the company to the Nasdaq National Market.

Wilson said, 'Studies have already shown that the consistent application of CBD to the skin can help provide significant targeted pain relief and inflammation relief in arthritic joints. That alone is immensely exciting, but to pair that potential with the dedication CBD Brands has to develop easy-to-use pharmaceutical quality CBD products provides many exciting opportunities.'